Get started
Author

Mariola Fotin‐Mleczek

Observed names: Fotin-Mleczek, Mariola, M. Fotin-Mleczek, Mariola Fotin-Mleczek, Mariola Fotin-mleczek
Institution: CureVac (Germany)
OpenAlex ID: A5057935520
A Comprehensive Model for the Cellular Uptake of Cationic Cell‐penetrating Peptides
2007 · Falk Duchardt, Mariola Fotin‐Mleczek, et al. · Traffic · 804
Developing mRNA-vaccine technologies
2012 · Thomas Schlake, Andreas Thess, et al. · RNA Biology · 636
PDF
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
2017 · Martin Alberer, Ulrike Gnad-Vogt, et al. · The Lancet · 548
Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
2015 · Andreas Thess, Stefanie Grund, et al. · Molecular Therapy · 519
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
2010 · Mariola Fotin-Mleczek, Katharina M. Duchardt, et al. · Journal of Immunotherapy · 340
Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8
2002 · Mariola Fotin-Mleczek, Frank Henkler, et al. · Journal of Cell Science · 293
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
2015 · Hubert Kübler, Birgit Scheel, et al. · Journal for ImmunoTherapy of Cancer · 289
PDF
A Stepwise Dissection of the Intracellular Fate of Cationic Cell-penetrating Peptides
2004 · Rainer Fischer, Karsten Köhler, et al. · Journal of Biological Chemistry · 282
PDF
Break on through to the Other Side—Biophysics and Cell Biology Shed Light on Cell‐Penetrating Peptides
2005 · Rainer Fischer, Mariola Fotin‐Mleczek, et al. · ChemBioChem · 273
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
2017 · Johannes Lutz, Sandra Lazzaro, et al. · npj Vaccines · 263
PDF
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
2019 · Alexandros Papachristofilou, Madeleine M. Hipp, et al. · Journal for ImmunoTherapy of Cancer · 233
PDF
A novel, disruptive vaccination technology
2013 · Karl-Josef Kallen, Regina Heidenreich, et al. · Human Vaccines & Immunotherapeutics · 224
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
2019 · Martin Sebastian, Andreas Schröder, et al. · Cancer Immunology Immunotherapy · 212
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
2021 · Peter G. Kremsner, Philipp Mann, et al. · Wiener klinische Wochenschrift · 203
PDF
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
2017 · Darin K. Edwards, Edith Jasny, et al. · Journal of Translational Medicine · 187
PDF
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
2017 · Moritz Thran, Jean Mukherjee, et al. · EMBO Molecular Medicine · 171
PDF
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
2021 · Susanne Rauch, Nicole Roth, et al. · npj Vaccines · 166
PDF
Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway
2011 · Christina Lorenz, Mariola Fotin-Mleczek, et al. · RNA Biology · 157
PDF
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
2014 · Martin Sebastian, Alexandros Papachristofilou, et al. · BMC Cancer · 143
PDF
Tumor Necrosis Factor Receptor-associated Factor (TRAF) 1 Regulates CD40-induced TRAF2-mediated NF-κB Activation
2003 · Mariola Fotin-Mleczek, Frank Henkler, et al. · Journal of Biological Chemistry · 111
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
2016 · Aleksandra Kowalczyk, Fatma Doener, et al. · Vaccine · 105
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
2012 · Mariola Fotin‐Mleczek, Kai Zanzinger, et al. · The Journal of Gene Medicine · 103
PDF
Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization
2005 · Mariola Fotin-Mleczek, Stefan Welte, et al. · Journal of Cell Science · 100
mRNA: A Novel Avenue to Antibody Therapy?
2019 · Thomas Schlake, Moritz Thran, et al. · Molecular Therapy · 93
PDF
A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
2014 · Regina Heidenreich, Edith Jasny, et al. · International Journal of Cancer · 80
Works count: 73
Citation count: 6,954
H-index: 31
I10-index: 38
Year
Topic
Type